Beaufort Securities Reiterates “Hold” Rating for AstraZeneca plc (AZN)
AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reaffirmed by investment analysts at Beaufort Securities in a research report issued to clients and investors on Friday.
AZN has been the subject of a number of other research reports. Deutsche Bank AG reaffirmed a “buy” rating and issued a GBX 5,800 ($72.46) price objective on shares of AstraZeneca plc in a report on Friday, July 29th. Sanford C. Bernstein set a GBX 5,333 ($66.63) price objective on shares of AstraZeneca plc and gave the company a “neutral” rating in a report on Wednesday, October 19th. Berenberg Bank set a GBX 5,550 ($69.34) price objective on shares of AstraZeneca plc and gave the company a “buy” rating in a report on Thursday, August 25th. Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc in a research report on Wednesday, July 27th. Finally, Goldman Sachs Group Inc. set a GBX 4,000 ($49.98) target price on shares of AstraZeneca plc and gave the company a “sell” rating in a research report on Wednesday, August 10th. Five research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. AstraZeneca plc presently has a consensus rating of “Hold” and an average target price of GBX 4,947.72 ($61.82).
Shares of AstraZeneca plc (LON:AZN) opened at 4350.00 on Friday. The stock’s market capitalization is GBX 55.03 billion. The company has a 50-day moving average of GBX 4,806.39 and a 200-day moving average of GBX 4,565.34. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.